Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study
Authors Zhang J, Li A, Jiang Q, Zheng F, Zhu H
Received 26 June 2019
Accepted for publication 28 October 2019
Published 15 November 2019 Volume 2019:13 Pages 3913—3918
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Sukesh Voruganti
Jindi Zhang,1,2,* Anyang Li,2,* Qi Jiang,2 Feiyun Zheng,2 Haiyan Zhu1,2
1Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Pudong, Shanghai 200126, People’s Republic of China; 2Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Haiyan Zhu
Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, 2699 Gaoke West Road, Pudong, Shanghai 200126, People’s Republic of China
Tel +86 137 5846 5255
Objective: To evaluate real-world use and outcomes of apatinib treatment in platinum-resistant recurrent epithelial ovarian cancer.
Methods: This is an observational study. Patients with platinum-resistant recurrent epithelial ovarian cancer initiating apatinib treatment from January 2016 to December 2018 were included. The primary end point was progression-free survival. Other end points included overall survival, objective response rate, disease control rate, and toxicity.
Results: A total of 28 platinum-resistant epithelial ovarian cancer patients were enrolled in this study. Thirteen cases received apatinib as maintenance therapy following chemotherapy with a median progression-free survival of 6.0 months and a medium overall survival of 11.0 months. Four patients received apatinib as palliative following chemotherapy with 2 cases in progressive disease and 2 cases in stable disease. Eleven cases received apatinib alone as salvage therapy with a disease control rate of 81.8% and a median progression-free survival of 3.0 months. The most common adverse effects were hand-foot syndrome (53.57%), secondary hypertension (46.43%) and fatigue (14.29%). Five patients discontinued treatment due to grade 3 toxicities and 4 patients required dose reduction because of adverse effects.
Conclusion: Apatinib produced moderate improvements in progression-free survival in patients with platinum-resistant epithelial ovarian cancer both as maintenance therapy following chemotherapy and as single-agent salvage therapy. Our study suggests that apatinib may be effective for women with platinum-resistant recurrent epithelial ovarian cancer.
Keywords: epidermal growth factor receptor, apatinib, ovarian cancer, platinum-resistant, maintenance therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]